Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

Satapathy, Mantosh Kumar; Yen, Ting-Lin; Jan, Jing-Shiun; Tang, Ruei-Dun; Wang, Jia Yi; Taliyan, Rajeev; Yang, Chih‐Hao

doi:10.3390/pharmaceutics13081183

Cited by 138 publications

(70 citation statements)

References 251 publications

(201 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microbial manipulation: microbiota transplant in GI disorders (269)(270)(271)(272) Microbial manipulation: microbiota transplant in neurodegenerative disorders (273)(274)(275)(276) Natural products in neurodegenerative disorders (277,278) Natural products in GI disorders (279,280) Dietary fibers in GI disorders (281) Nanotechnology and nanotheranostic approach in neurodegenerative disorders (282)(283)(284) Oxidized phospholipidis (285,286) SCFAs in GI inflammatory disorders (287)(288)(289) CD36 in Alzheimer's disease (290) Firmicutes Clostridiaceae Decreased in IBS (291) Increased in IBD (292,293) Increased in CD (293) Increased in Parkinson's disease (284,294) Increased in autism spectrum disorder (256,257) Decreased in bipolar disorder (258) Increases mucosal 5-HT and EC cells and decreased SERT expression (295) Correlated with increased levels of serotonin (263) Increases SERT expression (296) Lachnospiraceae Decreased in IBS (291) Decreased in IBD (293,297) Decreased in UC and CD (298) Not modified in CD (252) Increased in UC (252) Decreased in Parkinson's disease (259,…”

Section: -Ht Alterations Therapeutic Approachmentioning

confidence: 99%

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

et al. 2021

View full text Add to dashboard Cite

Disruption of the microbiota–gut–brain axis results in a wide range of pathologies that are affected, from the brain to the intestine. Gut hormones released by enteroendocrine cells to the gastrointestinal (GI) tract are important signaling molecules within this axis. In the search for the language that allows microbiota to communicate with the gut and the brain, serotonin seems to be the most important mediator. In recent years, serotonin has emerged as a key neurotransmitter in the gut–brain axis because it largely contributes to both GI and brain physiology. In addition, intestinal microbiota are crucial in serotonin signaling, which gives more relevance to the role of the serotonin as an important mediator in microbiota–host interactions. Despite the numerous investigations focused on the gut–brain axis and the pathologies associated, little is known regarding how serotonin can mediate in the microbiota–gut–brain axis. In this review, we will mainly discuss serotonergic system modulation by microbiota as a pathway of communication between intestinal microbes and the body on the microbiota–gut–brain axis, and we explore novel therapeutic approaches for GI diseases and mental disorders.

show abstract

Section: -Ht Alterations Therapeutic Approachmentioning

confidence: 99%

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The in vivo study confirmed the ability of the surface-tailored emulsomes to achieve improved VNP brain delivery compared to either oral market product or corresponding non-tailored formulations. PEG is able to target the brain endothelial cell receptors via induction of receptor-mediated transcytosis (Qiao et al., 2012 ; Pulgar, 2018 ), while SA targets the brain via the interaction with the negative charges existing on the BBB (Bors & Erdő, 2019 ; Satapathy et al., 2021 ), resulting in adsorptive-mediated endocytosis.…”

Section: Resultsmentioning

confidence: 99%

Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route: in vitro optimization and in vivo pharmacokinetic assessment

et al. 2022

View full text Add to dashboard Cite

Vinpocetine (VNP), a semisynthetic active pharmaceutical ingredient, is used for oral management of cerebrovascular diseases because of its ability to enhance the blood flow to the brain. However, despite that, the therapeutic application of VNP is restricted due to its reduced bioavailability and diminished brain levels that could be attributed to its low aqueous solubility, short half-life, and presystemic metabolism exposure. Accordingly, the goal of this work was to explore the ability of surface-tailored intranasal emulsomes to boost brain delivery of the drug. A 3 2 2 1 factorial design was implemented to explore the impact of phospholipid (PL) to solid lipid weight ratio, PL to cholesterol molar ratio, and type of solid lipid on vesicle size, zeta potential, drug entrapment, and release efficiency of the new developed VNP emulsomes. Tailoring of the optimized emulsomal surface formulation was performed using either cationization or PEGylation approaches to boost blood–brain barrier penetration. The pharmacokinetic assessment in rats showed significantly improved bioavailability of VNP emulsomal formulations compared to the oral market product. Additionally, surface-tailored emulsomes exhibited significantly higher brain levels compared to the optimized emulsomes. Based on these findings, the proposed surface-tailored emulsomes could be considered as a promising platform for achieving high brain levels of VNP following intranasal administration.

show abstract

“…The decision to give 3 mg of melatonin tablet every three hours between 24 hours and 48 hours, i.e., during the second day of the investigation, was to maintain the supraphysiological concen-tration of melatonin in blood plasma in order to see if it would affect the sleep. Melatonin per os has good tolerability and scarce evidence of side effects [9,10].…”

Section: Discussionmentioning

confidence: 99%

The High-Dose of Exogenous Melatonin Did Not Alter the Sleep-Wake Cycle in Anoxic Brain Injury Patients

et al. 2022

View full text Add to dashboard Cite

Disturbance in circadian rhythms and the sleep-wake cycle is typical for patients in the intensive care unit, which retards rehabilitation. To assess the effect of exogenous melatonin and simultaneous mitigation of intensive care unit environmental factors on sleep duration. We studied five patients with chronic disorder of consciousness caused by anoxic brain injury. In addition, we varied the level of melatonin secretion in blood plasma to assess melatonin’s bioavailability and elimination time. We evaluated the sleep-wake cycle using continuous videoelectroencephalogram monitoring with the addition of oculographic and myographic channels for 72 hours. All the patients received melatonin tablets on the second day, wore masks and ear plugs, and had no feeding and nursing manipulations at night on the second and third days. There was no significant difference in sleep time between the first, second, and third days. Future studies of the circadian rhythm should aim at gaining a deeper analysis of the characteristics of the sleep-wake cycle in patients with severe anoxic brain injury together with further research for possible ways to influence the circadian component of sleep.

show abstract

Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB

Cited by 138 publications

References 251 publications

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

Crosstalk Between Intestinal Serotonergic System and Pattern Recognition Receptors on the Microbiota–Gut–Brain Axis

Surface-tailoring of emulsomes for boosting brain delivery of vinpocetine via intranasal route: in vitro optimization and in vivo pharmacokinetic assessment

The High-Dose of Exogenous Melatonin Did Not Alter the Sleep-Wake Cycle in Anoxic Brain Injury Patients

Contact Info

Product

Resources

About